Disease on EC 3.4.22.26 - cancer procoagulant

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Cancer procoagulant in patients with adenocarcinomas.
Blood Coagulation Disorders
[Cancer procoagulant (CP)]
Breast Neoplasms
Activation of blood coagulation and the activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients.
The effect of cancer procoagulant on expression of metastatic and angiogenic markers in breast cancer and embryonic stem cell lines.
Carcinoma
A factor X-activating cysteine protease from malignant tissue.
A proteolytic procoagulant associated with malignant transformation.
Cancer procoagulant in serum of rats during development of experimental epithelioma.
Cysteine proteinase procoagulant from amnion-chorion.
Evidence of a warfarin-sensitive cancer procoagulant in V2 carcinoma.
Factor IXi-antithrombin (IXiAT) and thrombin-antithrombin (TAT) complexes in lung cancer patients.
gamma-Glutamyl carboxylase activity in experimental tumor tissues: a biochemical basis for vitamin K dependence of cancer procoagulant.
Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue.
Several murine metastasizing tumors possess a cysteine proteinase with cancer procoagulant characteristics.
[Cancer procoagulant activity in serum and neoplastic tissue in cases of cervical and uterine carcinoma]
Carcinosarcoma
Effect of immunisation with cancer procoagulant on the growth of Walker 256 carcinosarcoma cells in rats.
Colonic Neoplasms
[Diagnostic significance of cancer procoagulant activity in colorectal cancer]
Colorectal Neoplasms
Antioxidant potential in esophageal, stomach and colorectal cancers.
Cancer procoagulant as a marker in monitoring the therapy in cases of oesophageal, stomach and colorectal cancer.
[Cancer procoagulant activity in cases of esophageal, stomach and colorectal cancer considering progression degree and histological type of cancer]
[Diagnostic significance of cancer procoagulant activity in colorectal cancer]
Disseminated Intravascular Coagulation
Haemostatic problems in acute promyelocytic leukaemia.
[Expression of thrombogenic substances by neoplasms: TF and cancer procoagulant. Pathogenic effects.]
Esophageal Neoplasms
Antioxidant potential in esophageal, stomach and colorectal cancers.
[Diagnostic value of testing the procoagulant activity of neoplasms in cases of stomach and esophageal neoplasms]
Gastrointestinal Neoplasms
Antioxidant potential in esophageal, stomach and colorectal cancers.
Glioma
Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation.
Leiomyoma
Analysis of the relationship between cancer procoagulant activity and PCNA and Ki-67 expression in cases of common and cellular uterine leiomyomas.
The activity of cancer procoagulant in cases of uterine leiomyomas.
Leukemia
A new procoagulant in acute leukemia.
Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice.
Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells.
Cancer procoagulant in acute lymphoblastic leukemia.
Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid.
Syncope as Initial Presentation in an Undifferentiated Type Acute Myeloid Leukemia Patient with Acute Intracranial Hemorrhage.
Leukemia, Lymphoid
Cancer procoagulant in acute non lymphoid leukemia: relationship of enzyme detection to disease activity.
Leukemia, Promyelocytic, Acute
Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice.
Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells.
Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid.
Syncope as Initial Presentation in an Undifferentiated Type Acute Myeloid Leukemia Patient with Acute Intracranial Hemorrhage.
Lung Neoplasms
Activity of cancer procoagulant (CP) in serum of patients with cancer of lung, breast, oesophagus and colorectum.
Cancer procoagulant (CP) in lung cancer.
Melanoma
Cancer procoagulant (CP) analysis in human WM 115 malignant melanoma cells in vitro.
Cancer procoagulant and haemostatic abnormalities in melanoma.
Cancer procoagulant in human tumor cells: evidence from melanoma patients.
Direct analysis reveals an absence of gamma-carboxyglutamic acid in cancer procoagulant from human tissues.
Vitamin K-dependent procoagulant in cancer cells: a potential target for the antimetastatic effect of warfarin?
Myelodysplastic Syndromes
Assessment of coagulation disorders and cancer procoagulant activity in patients with myelodysplastic syndromes.
Neoplasm Metastasis
Cancer procoagulant as a marker in monitoring the therapy in cases of oesophageal, stomach and colorectal cancer.
The proteolytic profile of human cancer procoagulant suggests that it promotes cancer metastasis at the level of activation rather than degradation.
Usefulness of examination of some tumor markers in diagnostics of liver cancer.
Vitamin K-dependent procoagulant in cancer cells: a potential target for the antimetastatic effect of warfarin?
Neoplasms
A factor X-activating cysteine protease from malignant tissue.
A new procoagulant in acute leukemia.
A proteolytic procoagulant associated with malignant transformation.
Activation of blood coagulation and the activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients.
Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer.
Activity of cancer procoagulant (CP) in serum of patients with cancer of lung, breast, oesophagus and colorectum.
Acute lymphoblastic leukemia (ALL) and cancer procoagulant activity.
All trans-retinoic acid modulates the procoagulant activity of human breast cancer cells.
An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker.
Analysis of serum cancer procoagulant activity and its possible use as a tumor marker.
Analysis of the relationship between cancer procoagulant activity and PCNA and Ki-67 expression in cases of common and cellular uterine leiomyomas.
Antioxidant potential in esophageal, stomach and colorectal cancers.
Application of cancer procoagulant as an early detection tumor marker.
Arsenic trioxide downregulates cancer procoagulant activity in MCF-7 and WM-115 cell lines in vitro.
Assessment of coagulation disorders and cancer procoagulant activity in patients with myelodysplastic syndromes.
Biochemistry of cancer procoagulant.
Blood coagulation changes in nude mice bearing human colon carcinomas.
Cancer and the prothrombotic state.
Cancer and thromboembolic disease: pathogenic mechanisms.
Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice.
Cancer cell procoagulants and their pharmacological modulation.
Cancer procoagulant (CP) analysis in human WM 115 malignant melanoma cells in vitro.
Cancer procoagulant (CP) in lung cancer.
Cancer procoagulant A: a factor X activating procoagulant from malignant tissue.
Cancer procoagulant activity studies using synthetic peptidyl substrates.
Cancer procoagulant and blood platelet activation.
Cancer procoagulant and haemostatic abnormalities in melanoma.
Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells.
Cancer procoagulant as a marker in monitoring the therapy in cases of oesophageal, stomach and colorectal cancer.
Cancer procoagulant in acute lymphoblastic leukemia.
Cancer procoagulant in acute non lymphoid leukemia: relationship of enzyme detection to disease activity.
Cancer procoagulant in human tumor cells: evidence from melanoma patients.
Cancer procoagulant in patients with adenocarcinomas.
Cancer procoagulant in serum of rats during development of experimental epithelioma.
Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid.
Cancer procoagulant stimulates platelet adhesion.
Cancer procoagulant--CP.
Cancer procoagulant.
Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue.
Characterization of the cell-surface procoagulant activity of T-lymphoblastoid cell lines.
Coagulation proteases and human cancer.
Comparison of procoagulant activities in extracts of normal and malignant human tissue.
Comparison of properties of cancer procoagulant and human amnion-chorion procoagulant.
Cysteine proteinase procoagulant from amnion-chorion.
Diagnosis of cancer-associated vascular disorders.
Differential contribution of tissue factor and Factor XII to thrombin generation triggered by breast and pancreatic cancer cells.
Direct analysis reveals an absence of gamma-carboxyglutamic acid in cancer procoagulant from human tissues.
Early detection of relapse in acute non-lymphoblastic leukaemia patients by cancer procoagulant assay.
Effect of cancer procoagulant (CP) on the growth and adhesion of MCF-7 cells to vitronectin in vitro.
Effect of divalent ions on the activity of cancer procoagulant.
Effect of immunisation with cancer procoagulant on the growth of Walker 256 carcinosarcoma cells in rats.
Evidence of a warfarin-sensitive cancer procoagulant in V2 carcinoma.
Factor IXi-antithrombin (IXiAT) and thrombin-antithrombin (TAT) complexes in lung cancer patients.
Functional protease profiling with reporter peptides in serum specimens of colorectal cancer patients: demonstration of its routine diagnostic applicability.
gamma-Glutamyl carboxylase activity in experimental tumor tissues: a biochemical basis for vitamin K dependence of cancer procoagulant.
Generation of a monoclonal antibody that inhibits the procoagulant activity of various cancer cell lines.
Haemostatic problems in acute promyelocytic leukaemia.
In Vitro Screening of Synthetic Fluorogenic Substrates for Detection of Cancer Procoagulant Activity.
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Inhibition of cancer procoagulant by peptidyl diazomethyl ketones and peptidyl sulfonium salts.
Inhibitory properties of low molecular mass cysteine proteinase inhibitors from human sarcoma.
Intravascular clotting activation and bleeding in patients with hematologic malignancies.
Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue.
New immunocapture enzyme (ICE) assay for quantification of cancer procoagulant activity: studies of inhibitors.
New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia.
Pathogenesis of increased risk of thrombosis in cancer.
Procoagulant activity of mouse transformed cells: different expression in freshly isolated or cultured cells.
Procoagulant factors in patients with cancer.
Promotion of metastasis by a specific complex of coagulation factors may be independent of fibrin formation.
Properties of proteins in cancer procoagulant preparations that are detected by anti-tissue factor antibodies.
Prostate-specific antigen, prostate cancer, and disorders of hemostasis.
Rat prostate tumors express cancer procoagulant, an activator of coagulation factor X.
Role of phosphoinositide 3-kinase in adhesion of platelets to fibrinogen stimulated by cancer procoagulant.
Several murine metastasizing tumors possess a cysteine proteinase with cancer procoagulant characteristics.
Substrate optimization and clinical validation of reporter peptides for MS-based protease profiling in serum specimens: a new approach for diagnosis of malignant disease.
Syncope as Initial Presentation in an Undifferentiated Type Acute Myeloid Leukemia Patient with Acute Intracranial Hemorrhage.
The activity of cancer procoagulant in cases of uterine leiomyomas.
The effect of cancer procoagulant on expression of metastatic and angiogenic markers in breast cancer and embryonic stem cell lines.
The mechanism of melanoma-associated thrombin activity and von Willebrand factor release from endothelial cells.
The Pathogenetic Role of Apoptosis in Hypercoagulable States.
The proteolytic profile of human cancer procoagulant suggests that it promotes cancer metastasis at the level of activation rather than degradation.
The prothrombotic state in cancer: pathogenic mechanisms.
The purification and properties of cancer procoagulant from murine tumors.
The site of activation of factor X by cancer procoagulant.
Three-stage chromogenic assay for the analysis of activation properties of factor X by cancer procoagulant.
Thrombin generation in children with acute lymphoblastic leukemia: effect of leukemia immunophenotypic subgroups.
Thrombosis in cancer patients.
Thrombosis in leukemia: incidence, causes, and practical management.
Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation.
Update on tumor cell procoagulant factors.
Usefulness of examination of some tumor markers in diagnostics of liver cancer.
Venous thromboembolism in patients with cancer and its relationship to the coagulation cascade and vascular endothelial growth factor.
Vitamin K-dependent procoagulant in cancer cells: a potential target for the antimetastatic effect of warfarin?
[Activation of blood coagulation in oncology patients]
[Assessment of the efficacy of cancer procoagulant (CP) activity evaluation in the oncological diagnosis of the urinary system]
[Cancer procoagulant (CP): the new biochemical marker in oncologic diagnosis]
[Cancer procoagulant (CP)]
[Cancer procoagulant activity in cases of esophageal, stomach and colorectal cancer considering progression degree and histological type of cancer]
[Cancer procoagulant activity in serum and neoplastic tissue in cases of cervical and uterine carcinoma]
[Cancer procoagulant and cathepsin D activity in blood serum in patients with bladder cancer]
[Chemotherapeutics increasing the risk of thromboembolic complications. The necessity of anticoagulant profilaxis during chemotherapy]
[Diagnostic significance of cancer procoagulant activity in colorectal cancer]
[Diagnostic value of testing the procoagulant activity of neoplasms in cases of stomach and esophageal neoplasms]
[Evaluation of diagnostic values of neoplastic procoagulant in pancreatic, hepatic and ovary cancers]
[Expression of thrombogenic substances by neoplasms: TF and cancer procoagulant. Pathogenic effects.]
[Functions of inflammatory factor in non-tumor deep venous thrombosis of lower extremity].
[Malignancy and thrombosis: a double-sided clinical relationship]
[Paraneoplastic syndrome hematologic abnormalities]
[Usefulness of detecting cancer procoagulant activity and thyrotropic hormone concentration in the differentiation of tumor-like changes in the thyroid]
Ovarian Neoplasms
[Evaluation of diagnostic values of neoplastic procoagulant in pancreatic, hepatic and ovary cancers]
Paraproteinemias
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute lymphoblastic leukemia (ALL) and cancer procoagulant activity.
Cancer procoagulant in acute lymphoblastic leukemia.
Thromboembolism
Venous thromboembolism in patients with cancer and its relationship to the coagulation cascade and vascular endothelial growth factor.
Thrombophilia
[Malignancy and thrombosis: a double-sided clinical relationship]
Thrombosis
Thrombosis in leukemia: incidence, causes, and practical management.
Urinary Bladder Neoplasms
[Cancer procoagulant and cathepsin D activity in blood serum in patients with bladder cancer]
Venous Thrombosis
[Functions of inflammatory factor in non-tumor deep venous thrombosis of lower extremity].